Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.60 USD
Change Today +0.03 / 1.91%
Volume 920.9K
CTIC On Other Exchanges
Symbol
Exchange
BrsaItaliana
NASDAQ CM
Frankfurt
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

cti biopharma corp (CTIC) Snapshot

Open
$1.60
Previous Close
$1.57
Day High
$1.61
Day Low
$1.55
52 Week High
03/9/15 - $2.94
52 Week Low
08/26/15 - $1.50
Market Cap
289.1M
Average Volume 10 Days
1.7M
EPS TTM
$-0.50
Shares Outstanding
180.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CTI BIOPHARMA CORP (CTIC)

Related News

No related news articles were found.

cti biopharma corp (CTIC) Related Businessweek News

No Related Businessweek News Found

cti biopharma corp (CTIC) Details

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an oral multikinase inhibitor with activity against Janus Kinase 2 and FMS-like tyrosine kinase, which is in Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II/III clinical trials for the treatment of acute myeloid leukemia; and Opaxio, a chemotherapeutic agent, which is in Phase III clinical trials for the treatment of various solid tumors, including non-small cell lung, ovarian, breast, and prostate cancers. The company has development, commercialization, and license agreement with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA for the development and commercialization of pacritinib for use in oncology and other therapeutic areas. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

132 Employees
Last Reported Date: 03/12/15
Founded in 1991

cti biopharma corp (CTIC) Top Compensated Officers

Principal Founder, Chief Executive Officer, P...
Total Annual Compensation: $1.3M
Co-Founder, Principal Financial Officer, Prin...
Total Annual Compensation: $594.0K
Co-Founder, Interim Chief Medical Officer, Ch...
Total Annual Compensation: $545.8K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $544.4K
Compensation as of Fiscal Year 2014.

cti biopharma corp (CTIC) Key Developments

CTI BioPharma Corp. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2015 ; Reaffirms Earnings Guidance for the Year 2015

CTI BioPharma Corp. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $1,100,000, loss from operations of $31,027,000, net loss of $32,596,000 or $0.19 per basic and diluted share compared to the total revenues of $1,343,000, loss from operations of $26,668,000, net loss of $27,399,000 or $0.19 per basic and diluted share for the same quarter a year ago. For the six months period, the company reported total revenues of $3,828,000, loss from operations of $58,510,000, net loss of $61,193,000 or $0.35 per basic and diluted share compared to the total revenues of $2,754,000, loss from operations of $54,331,000, net loss of $56,401,000 or $0.39 per basic and diluted share for the same period a year ago. The company reaffirmed prior financial guidance that it expects total revenues for 2015 will be approximately $50 million to $55 million, and it expects that non-GAAP operating loss for 2015 will be approximately $75 million to $85 million, which excludes non-cash share-based compensation expense. These financial projections are primarily based on factors previously outlined in the Company’s fourth quarter and full year 2014 financial results press release.

CTI BioPharma Corp. to Report Q2, 2015 Results on Aug 06, 2015

CTI BioPharma Corp. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 06, 2015

CTI BioPharma Corp., Q2 2015 Earnings Call, Aug 06, 2015

CTI BioPharma Corp., Q2 2015 Earnings Call, Aug 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CTIC:US $1.60 USD +0.03

CTIC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Curis Inc $2.59 USD +0.09
Cytokinetics Inc $7.00 USD +0.22
Navidea Biopharmaceuticals Inc $1.82 USD +0.02
Progenics Pharmaceuticals Inc $7.67 USD -0.16
Rigel Pharmaceuticals Inc $2.99 USD +0.12
View Industry Companies
 

Industry Analysis

CTIC

Industry Average

Valuation CTIC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CTI BIOPHARMA CORP, please visit www.ctibiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.